Comparison

Nazartinib mesylate European Partner

Item no. HY-12872A-50mg
Manufacturer MedChem Express
CASRN 1508250-72-3
Amount 50mg
Quantity options 100 mg 10mg 1 ea 1mg 25mg 50mg 5mg
Category
Type Inhibitors
Specific against other
Citations [1]Lelais G, et al. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T79<br>[2]Jia Y, et al. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Res. 2016 Mar 15;76(6):1591-602
Smiles O=C(C1=CC(C)=NC=C1)NC2=NC3=CC=CC(Cl)=C3N2[C@H]4CN(C(/C=C/CN(C)C)=O)CCCC4.CS(=O)(O)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias EGF816 (mesylate)
Available
Product Description
Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min−1 on EGFR(L858R/790M) mutant, respectively.
Shipping
Room temperature
Manufacturers Applications
Cancer-Kinase/protease
MolecularWeight
591.12
Clinical_Information
Phase 2
Manufacturers Research Area
Cancer
Solubility
10 mM in DMSO
Manufacturers Target
EGFR
Isoform
EGFR/ErbB1/HER1
Pathway
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close